Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women.
Chinese visceral adipose index
early postmenopausal women
metabolic dysfunction associated fatty liver disease
obesity indices
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
12
2022
accepted:
24
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Previous studies have reported the diagnostic values of multiple obesity indicators for predicting the risk of non-alcoholic fatty liver disease. However, the diagnostic values of obesity indicators for predicting the risk of metabolic dysfunction-associated fatty liver disease (MAFLD) in early postmenopausal women is still unknown. Therefore, this study investigated the predictive values of common obesity indices for estimating the risk of MAFLD in early postmenopausal Chinese women. This study enrolled 2514 early postmenopausal women, aged between 45 and 55 years, who underwent abdominal ultrasonography examination at the Health examination center of the Huadong Sanatorium between June 2021 and December 2021. The values for six obesity indices, namely, body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), body adiposity index (BAI), and Chinese visceral adiposity index (CVAI) were extracted from the medical records. Our data showed that all the six obesity indices were significantly associated with the risk of MAFLD ( This study demonstrated that all the obesity indices were associated with an increased risk of MAFLD in the obese subjects and five obesity indices except for BAI were associated with an increased risk of MAFLD in the lean subjects among the early postmenopausal women. CVAI showed the strongest predictive performance in estimating the risk of MAFLD among early menopausal women.
Sections du résumé
Background
UNASSIGNED
Previous studies have reported the diagnostic values of multiple obesity indicators for predicting the risk of non-alcoholic fatty liver disease. However, the diagnostic values of obesity indicators for predicting the risk of metabolic dysfunction-associated fatty liver disease (MAFLD) in early postmenopausal women is still unknown. Therefore, this study investigated the predictive values of common obesity indices for estimating the risk of MAFLD in early postmenopausal Chinese women.
Methods
UNASSIGNED
This study enrolled 2514 early postmenopausal women, aged between 45 and 55 years, who underwent abdominal ultrasonography examination at the Health examination center of the Huadong Sanatorium between June 2021 and December 2021. The values for six obesity indices, namely, body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), body adiposity index (BAI), and Chinese visceral adiposity index (CVAI) were extracted from the medical records.
Results
UNASSIGNED
Our data showed that all the six obesity indices were significantly associated with the risk of MAFLD (
Conclusion
UNASSIGNED
This study demonstrated that all the obesity indices were associated with an increased risk of MAFLD in the obese subjects and five obesity indices except for BAI were associated with an increased risk of MAFLD in the lean subjects among the early postmenopausal women. CVAI showed the strongest predictive performance in estimating the risk of MAFLD among early menopausal women.
Identifiants
pubmed: 36909348
doi: 10.2147/DMSO.S402814
pii: 402814
pmc: PMC9999715
doi:
Types de publication
Journal Article
Langues
eng
Pagination
607-617Informations de copyright
© 2023 Lu et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
J Clin Transl Hepatol. 2022 Aug 28;10(4):595-599
pubmed: 36062272
BMC Gastroenterol. 2017 Nov 29;17(1):135
pubmed: 29187144
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Front Endocrinol (Lausanne). 2022 Oct 05;13:959860
pubmed: 36277708
Int J Gynaecol Obstet. 2017 Aug;138(2):201-206
pubmed: 28494104
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Clin Invest. 1995 Jan;95(1):158-66
pubmed: 7814610
Curr Obes Rep. 2019 Sep;8(3):243-254
pubmed: 31144261
Hepatobiliary Pancreat Dis Int. 2022 Jun;21(3):241-247
pubmed: 35365418
Life (Basel). 2022 May 11;12(5):
pubmed: 35629385
Hepatol Int. 2020 Dec;14(6):889-919
pubmed: 33006093
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Diabetes Metab Res Rev. 2018 Oct;34(7):e3048
pubmed: 30035847
J Physiol. 2019 Aug;597(15):3885-3903
pubmed: 31206703
Front Endocrinol (Lausanne). 2022 Jun 30;13:921997
pubmed: 35846316
Lipids Health Dis. 2021 Oct 10;20(1):134
pubmed: 34629059
Lipids Health Dis. 2021 Oct 27;20(1):145
pubmed: 34706716
Clin Mol Hepatol. 2021 Apr;27(2):257-269
pubmed: 33751877
Exp Diabetes Res. 2012;2012:859395
pubmed: 22778716
Am J Clin Nutr. 2008 Nov;88(5):1263-71
pubmed: 18996861
Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398
pubmed: 30902670
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Metabolism. 2021 Oct;123:154868
pubmed: 34400217
BMC Gastroenterol. 2021 May 10;21(1):212
pubmed: 33971822
Obesity (Silver Spring). 2010 Jul;18(7):1336-40
pubmed: 19910940
BMC Gastroenterol. 2022 Nov 19;22(1):471
pubmed: 36402947
Liver Int. 2020 Dec;40(12):3018-3030
pubmed: 32997882
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Liver Int. 2020 Sep;40(9):2082-2089
pubmed: 32478487
Rev Assoc Med Bras (1992). 2021 Apr;67(4):549-554
pubmed: 34495059
Exp Gerontol. 2020 Oct 1;139:111019
pubmed: 32663589
Oxid Med Cell Longev. 2018 Jun 11;2018:9547613
pubmed: 29991976
World J Hepatol. 2018 Oct 27;10(10):695-701
pubmed: 30386462
J Clin Transl Hepatol. 2021 Dec 28;9(6):972-982
pubmed: 34966660
J Clin Endocrinol Metab. 2011 Feb;96(2):541-7
pubmed: 21123445
Br J Nutr. 2021 Aug 28;126(4):612-620
pubmed: 33143773
Diabetes Metab Res Rev. 2021 Feb;37(2):e3370
pubmed: 32562335
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
BMC Endocr Disord. 2022 Mar 14;22(1):63
pubmed: 35287643
Diabetes Metab Syndr Obes. 2021 Jun 10;14:2631-2639
pubmed: 34140792
Diabetes Metab Syndr Obes. 2021 Aug 24;14:3743-3751
pubmed: 34466009